http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008021847-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4aec50be8d53d5af85962f97fb155420 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 |
| filingDate | 2007-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a13451441dc186d29752a61799847f55 |
| publicationDate | 2008-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008021847-A2 |
| titleOfInvention | Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent |
| abstract | A composition of multilamellar vesicles for the delivery of pharmaceutically-active substances through the skin of a mammal, the composition including between about 1 to about 30% Cyclomethicone 5-.N.F., between about 1 to about 30% PEG-12 Dimethicone; between about 3 to about 14% Cyclopentasiloxane and PEG 12 Dimethicone Crosspolymers, between about 0.9 to about 9% Lauryl PEG/PPG - 18/18 Methicone, between about 2 to 5% Sepigel 305, between about 1 to about 4%, Carbopol ETD 2020 solution (2%), up to 100% Water, and Sodium hydroxide to a pH between about 6-6.5. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2484068-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022387594-A1 |
| priorityDate | 2006-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.